Technical Modification in the Intracarotid Chemotherapy and Osmotic Blood-Brain Barrier Disruption Procedure to Prevent the Relapse of Carboplatin-Induced Orbital Pseudotumor

References

1. ↵
   Miller NR, Newman NJ. Walsh & Hoyst’s clinical neuro-ophthalmology: the essentials. 5th edition. Philadelphia: Lippincott, Williams and Wilkins;1998 :677–679
2. Lee MS, Lessell S. Orbital myositis posing as cluster headache. Arch Neurol 2002;59:635–636

   CrossRefPubMedWeb of Science
3. ↵
   Maurer I, Zierz SJ. Recurrent orbital myositis: report of a familial incidence. Arch Neurol 1999;56:1407–1409

   CrossRefPubMedWeb of Science
4. ↵
   Nabili S, McCarey DW, Browne B, Capell HA. A case of orbital myositis associated with rheumatoid arthritis. Ann Rheum Dis 2002;61:938–939

   FREE Full Text
5. ↵
   Pollard Z. Acute rectus muscle palsy in children as a result of orbital myositis. J Pediatr 1996;128:230–233

   PubMed
6. ↵
   Kupersmith MJ, Frohman LP, Choi IS, et al. Visual system toxicity following intra-arterial chemotherapy. Neurology 1988;38:284–289

   Abstract/FREE Full Text
7. ↵
   Margo CE, Murtagh FR. Ocular and orbital toxicity after intracarotid cisplatin therapy. Am J Ophthalmol 1993;116:508–509

   PubMedWeb of Science
8. ↵
   Wu HM, Lee AG, Lehane DE et al. Ocular and orbital complications of intraarterial cisplatin. J Neuroophthalmol 1997;17:195–198

   PubMed
9. ↵
   O’Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000;59(Suppl)4:S19–S27
10. Selvaratnam G, Philips RH, Mohamed AK, Radzi A. Adverse effects of cytotoxics-platinum agents. Adverse Drug React Toxicol Rev 1997;16:171–197

    PubMed
11. ↵
    Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409–422

    Abstract/FREE Full Text
12. ↵
    Yung WKA, Mechitler Laszlo, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991;9:860–864

    Abstract
13. Twelves CJ, Ash CM, Miles DW, et al. Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma. Cancer Chemother Pharmacol 1991;27:481–483

    PubMed
14. Warnick RE, Prados MD, Mack EE, et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neuro-Oncol 1994;19:69–74

    CrossRefPubMed
15. Lunardi P, Farah JO, Mastronardi L, et al. Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study. Acta Neurochirurgica 1996;138:215–220

    PubMed
16. Prados MD, Warnick RE, Mack EE, et al. Intravenous carboplatin for recurrent gliomas. Am J Clin Oncol 1996;19:609–612

    CrossRefPubMedWeb of Science
17. Friedman HS, Shelley L, Rasheed K, Friedman AH. Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Med Pediatr Oncol 1998;31:16–18

    CrossRefPubMedWeb of Science
18. ↵
    Huncharedk M, Kupelnick B, Bishop D. Platinum analogues in the treatment of recurrent high grade astrocytoma. Cancer Treat Rev 1998;24:307–316

    PubMed
19. ↵
    Williams PC, Henner WD, Roman-Goldstein S, et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 1995;37:17–27

    PubMedWeb of Science
20. ↵
    Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000;88:637–647

    CrossRefPubMedWeb of Science
21. ↵
    Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998;42:1083–1100

    CrossRefPubMedWeb of Science
22. ↵
    Fortin D, McAllister LD, Nesbit G, et al. Unusual cervical spine cord toxicity associated with intra-arterial carboplatin, intra-arterial or intravenous etoposide phosphate, and intravenous cyclophosphamide with osmotic blood brain-barrier disruption in the vertebral artery. AJNR Am J Neuroradiol 1999;20:1794–1802

    Abstract/FREE Full Text
23. ↵
    Desjardins A, Boudrias M, Fortin D. Osmotic blood-brain barrier disruption to enhance chemotherapy delivery in the treatment of brain tumors: the Sherbrooke experience. A-07. Can J Neurol Sci 2002; (Suppl 1):S9
24. ↵
    Fortin D, Neuwelt EA Therapeutic Manipulation of the Blood-Brain Barrier: Neurobase-Neurosurgery. 1st ed. San Diego: Medlink Neurology;2002
25. ↵
    Silbergeld DL, Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 1997;86:525–531

    PubMedWeb of Science
26. ↵
    McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000;46:51–61

    CrossRefPubMedWeb of Science